Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy

NCT04624256 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04624256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 10, 2020
Completion date
December 31, 2028
Enrollment
208 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage i prostate cancer american joint committee on cancer (ajcc) v8, stage ii prostate cancer ajcc v8, stage iia prostate cancer ajcc v8, stage iib prostate cancer ajcc v8, stage iic prostate cancer ajcc v8